TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01564719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic health
Description: The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic health
Description: The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
Study: NCT04358978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with posterior mesh no attachment
Description: pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with posterior mesh attachment
Description: pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
Study: NCT01564719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic health
Description: The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
Study: NCT01594684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug coated balloon inflation (Cotavance, Medrad Inc.)
Description: Balloon inflation
Study: NCT03592862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: Oral capsule
Study: NCT01594684

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: uncoated balloon (e.g. Admiral, Medtronic)
Description: balloon inflation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)
Description: ballon inflation
Study: NCT01609140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen A, repeating subcutaneous injections every 4 weeks
Study: NCT03592862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT04439734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation
Description: WB-EMS once per week 20 min for 16 weeks
Study: NCT02675777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Intervention
Description: Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)
Study: NCT04207073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilization of median nerve
Description: Neural mobilization
Study: NCT03669393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-317 8mg
Description: 3 intravitreal injections of THR-317 8mg, approximately 1 month apart
Study: NCT01880450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Prepared
Description: Behavioral intervention to reduce sexual risk and promote healthy relationships

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEEN
Description: Control condition the promote communication, decision-making skills etc.
Study: NCT02277171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide impregnated catheter
Description: Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
Study: NCT01468519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin via continuous subcutaneous insulin infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin via multiple daily injections
Study: NCT01535937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg IV over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.025 mg/kg IV over 40 minutes
Study: NCT02333838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Thiotepa
Description: IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Fludarabine
Description: IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Busulfan
Description: (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
Study: NCT01609140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen E, repeating subcutaneous injections every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen D, repeating subcutaneous injections every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen C, repeating subcutaneous injections every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPSK3169A
Description: Dose regimen B, repeating subcutaneous injections every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeating subcutaneous injections of placebo every 4 weeks
Study: NCT04607382

Intervention type: DRUG
Intervention: LEP
Description: LEP dosage up to the discretion of the treating gynecologists.

Intervention type: DRUG
Intervention: NSAIDs and/or Chinese medicine (CM)
Description: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
Study: NCT02333838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Anti-thymocyte globuline
Description: (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
Study: NCT04348903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
Study: NCT02603887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04348903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Pre-Visit Imagery Intervention
Description: Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
Study: NCT01984814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
Study: NCT00736229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
Study: NCT04520789

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RPE cell collection and single cell heterogeneity study
Description: Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: RPE cell collection and single cell heterogeneity study
Description: Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative intervention
Description: Early local steroids drug intervention in patients with severe postoperative PVR

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery for Retinal Detachment
Description: Conventional Surgery for Retinal Detachment
Study: NCT02330029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pinaverium
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atractylodes
Description: Atractylodes (\~10-15g)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paeonia Lactiflora
Description: Paeonia Lactiflora (\~15-30g)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tangerine Peel
Description: Tangerine Peel (\~10g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledebouriella Root
Description: Ledebouriella Root (\~10g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix codonopsitis
Description: Radix codonopsitis (\~10-15g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix curcumae
Description: Radix curcumae (\~10g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingered citron
Description: Fingered citron (\~10g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tuckahoe
Description: Tuckahoe (15g)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is blindly given to patients.
Study: NCT00815789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored cardiovascular risk management (Nurse-administered )
Description: A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
Study: NCT02167061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 fed
Study: NCT00637728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 110 mg/mL
Description: Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 5 mL once daily
Study: NCT01901744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Study: NCT03823638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral D-Mannitol of Placebo
Description: Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral D-Mannitol of Placebo
Description: Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
Study: NCT03502746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg, IV over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8mg/kg, IV over 60 minutes.
Study: NCT03668132

Intervention type: OTHER
Intervention: ischemic brain damage
Description: Have or not have the ischemic brain damage and the location of the damage
Study: NCT01137760

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 5 g of sucrose daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Description: 2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Description: 5.0 g galactooligosaccharide daily for 8 weeks
Study: NCT05132452

Intervention type: DIAGNOSTIC_TEST
Intervention: The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)
Description: Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
Study: NCT03975114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Any approved first line chemotherapy regimen at Investigators' choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Any approved first line chemotherapy regimen at Investigators' choice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Any approved first line chemotherapy regimen at Investigators' choice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
Study: NCT04221152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Tablets
Description: The administration is oral administration with water before or after breakfast.
Study: NCT04093284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The needle-free jet injector
Description: Continuous insulin therapy for 9 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The needle-free jet injector
Description: Continuous insulin therapy for 9 days
Study: NCT02016508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous bone marrow derived stem cells
Description: intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
Study: NCT01532375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang
Description: Kochujang (32g/day) for 12weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo(32g/day) for 12weeks
Study: NCT00311805

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells (CD34+)
Description: Intramuscular Injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells (CD34+)
Description: Intramuscular Injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Stem Cells (CD34+)
Description: Intramuscular Injections
Study: NCT02663440

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Hypofractionated IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage Colony-stimulating Factor
Description: Granulocyte-macrophage Colony-stimulating Factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide
Study: NCT02769052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy through self-applied device .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy through self-applied device .
Study: NCT01799278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237
Description: MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
Study: NCT02846727

Intervention type: DEVICE
Intervention: skin perfusion image
Description: Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.

Intervention type: DEVICE
Intervention: skin perfusion image
Description: Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
Study: NCT02665455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed.
Study: NCT03331588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subxiphoid uniportal VATS
Description: Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal uniportal VATS
Description: The surgical procedures followed principles of pulmonary resections
Study: NCT04374552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate &Azithromycin
Description: Drug - Hydroxychloroquine sulfate \&Azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug - placebo
Study: NCT02269488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3250
Description: MEDI3250
Study: NCT00469729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: StemEx®
Description: The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.